These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 24943989)

  • 1. Pyroglutamate-amyloid-β and glutaminyl cyclase are colocalized with amyloid-β in secretory vesicles and undergo activity-dependent, regulated secretion.
    Cynis H; Funkelstein L; Toneff T; Mosier C; Ziegler M; Koch B; Demuth HU; Hook V
    Neurodegener Dis; 2014; 14(2):85-97. PubMed ID: 24943989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-amyloid peptides undergo regulated co-secretion with neuropeptide and catecholamine neurotransmitters.
    Toneff T; Funkelstein L; Mosier C; Abagyan A; Ziegler M; Hook V
    Peptides; 2013 Aug; 46():126-35. PubMed ID: 23747840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer's disease.
    Morawski M; Schilling S; Kreuzberger M; Waniek A; Jäger C; Koch B; Cynis H; Kehlen A; Arendt T; Hartlage-Rübsamen M; Demuth HU; Roßner S
    J Alzheimers Dis; 2014; 39(2):385-400. PubMed ID: 24164736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms.
    Hartlage-Rübsamen M; Morawski M; Waniek A; Jäger C; Zeitschel U; Koch B; Cynis H; Schilling S; Schliebs R; Demuth HU; Rossner S
    Acta Neuropathol; 2011 Jun; 121(6):705-19. PubMed ID: 21301857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells.
    Cynis H; Schilling S; Bodnár M; Hoffmann T; Heiser U; Saido TC; Demuth HU
    Biochim Biophys Acta; 2006 Oct; 1764(10):1618-25. PubMed ID: 17005457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta.
    Cynis H; Scheel E; Saido TC; Schilling S; Demuth HU
    Biochemistry; 2008 Jul; 47(28):7405-13. PubMed ID: 18570439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic.
    Hook G; Yu J; Toneff T; Kindy M; Hook V
    J Alzheimers Dis; 2014; 41(1):129-49. PubMed ID: 24595198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of glutaminyl cyclase prevents pGlu-Abeta formation after intracortical/hippocampal microinjection in vivo/in situ.
    Schilling S; Appl T; Hoffmann T; Cynis H; Schulz K; Jagla W; Friedrich D; Wermann M; Buchholz M; Heiser U; von Hörsten S; Demuth HU
    J Neurochem; 2008 Aug; 106(3):1225-36. PubMed ID: 18627432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl-Peptidase Activity of Meprin β Links N-truncation of Aβ with Glutaminyl Cyclase-Catalyzed pGlu-Aβ Formation.
    Schlenzig D; Cynis H; Hartlage-Rübsamen M; Zeitschel U; Menge K; Fothe A; Ramsbeck D; Spahn C; Wermann M; Roßner S; Buchholz M; Schilling S; Demuth HU
    J Alzheimers Dis; 2018; 66(1):359-375. PubMed ID: 30320570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease.
    Morawski M; Hartlage-Rübsamen M; Jäger C; Waniek A; Schilling S; Schwab C; McGeer PL; Arendt T; Demuth HU; Rossner S
    Acta Neuropathol; 2010 Aug; 120(2):195-207. PubMed ID: 20383514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation.
    Hartlage-Rübsamen M; Bluhm A; Piechotta A; Linnert M; Rahfeld JU; Demuth HU; Lues I; Kuhn PH; Lichtenthaler SF; Roßner S; Höfling C
    Molecules; 2018 Apr; 23(4):. PubMed ID: 29673150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-amyloid peptide in regulated secretory vesicles of chromaffin cells: evidence for multiple cysteine proteolytic activities in distinct pathways for beta-secretase activity in chromaffin vesicles.
    Hook VY; Toneff T; Aaron W; Yasothornsrikul S; Bundey R; Reisine T
    J Neurochem; 2002 Apr; 81(2):237-56. PubMed ID: 12064471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concerted action of dipeptidyl peptidase IV and glutaminyl cyclase results in formation of pyroglutamate-modified amyloid peptides in vitro.
    Antonyan A; Schlenzig D; Schilling S; Naumann M; Sharoyan S; Mardanyan S; Demuth HU
    Neurochem Int; 2018 Feb; 113():112-119. PubMed ID: 29224965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice.
    Jawhar S; Wirths O; Schilling S; Graubner S; Demuth HU; Bayer TA
    J Biol Chem; 2011 Feb; 286(6):4454-60. PubMed ID: 21148560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration.
    Becker A; Kohlmann S; Alexandru A; Jagla W; Canneva F; Bäuscher C; Cynis H; Sedlmeier R; Graubner S; Schilling S; Demuth HU; von Hörsten S
    BMC Neurosci; 2013 Oct; 14():108. PubMed ID: 24083638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the binding mode of PQ912 against secretory glutaminyl cyclase through systematic exploitation of conformational ensembles.
    Chandran R; Dileep KV
    Chem Biol Drug Des; 2021 Nov; 98(5):850-856. PubMed ID: 34423556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Piperidine-4-carboxamide as a new scaffold for designing secretory glutaminyl cyclase inhibitors.
    Dileep KV; Sakai N; Ihara K; Kato-Murayama M; Nakata A; Ito A; Sivaraman DM; Shin JW; Yoshida M; Shirouzu M; Zhang KYJ
    Int J Biol Macromol; 2021 Feb; 170():415-423. PubMed ID: 33373636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human glutaminyl cyclase: Structure, function, inhibitors and involvement in Alzheimer's disease.
    Vijayan DK; Zhang KYJ
    Pharmacol Res; 2019 Sep; 147():104342. PubMed ID: 31288079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Potent Human Glutaminyl Cyclase Inhibitors as Anti-Alzheimer's Agents Based on Rational Design.
    Hoang VH; Tran PT; Cui M; Ngo VT; Ann J; Park J; Lee J; Choi K; Cho H; Kim H; Ha HJ; Hong HS; Choi S; Kim YH; Lee J
    J Med Chem; 2017 Mar; 60(6):2573-2590. PubMed ID: 28234463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent human glutaminyl cyclase inhibitors as potential anti-Alzheimer's agents: Structure-activity relationship study of Arg-mimetic region.
    Ngo VTH; Hoang VH; Tran PT; Ann J; Cui M; Park G; Choi S; Lee J; Kim H; Ha HJ; Choi K; Kim YH; Lee J
    Bioorg Med Chem; 2018 Mar; 26(5):1035-1049. PubMed ID: 29398442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.